Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial

Purpose To determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Eye (London) 2016-10, Vol.30 (10), p.1343-1350
Hauptverfasser:	Fechtner, R D, Myers, J S, Hubatsch, D A, Budenz, D L, DuBiner, H B
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/3161/3169 692/699/3161/3169/3170 Adrenergic alpha-2 Receptor Agonists Adult Aged Aged, 80 and over Antihypertensive Agents - therapeutic use Brimonidine Tartrate - therapeutic use Carbonic Anhydrase Inhibitors Clinical Study Double-Blind Method Drug Combinations Female Glaucoma, Open-Angle - diagnosis Glaucoma, Open-Angle - drug therapy Humans Intraocular Pressure - drug effects Laboratory Medicine Male Medicine Medicine & Public Health Middle Aged Ocular Hypertension - diagnosis Ocular Hypertension - drug therapy Ophthalmic Solutions Ophthalmology Pharmaceutical Sciences/Technology Prostaglandins F, Synthetic - therapeutic use Sulfonamides - therapeutic use Surgery Surgical Oncology Thiazines - therapeutic use Tonometry, Ocular Travoprost - therapeutic use Visual Acuity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose To determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapy Methods This 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults with open-angle glaucoma or ocular hypertension and with mean IOP ≥21 and
ISSN:	0950-222X 1476-5454
DOI:	10.1038/eye.2016.126